Dechert Advises Leerink Swann, Cowen and Company as Underwriters in Amicus Therapeutics $54 Million Underwritten Offering of Common Stock
March 2, 2012
Dechert News Release
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company that develops therapies for rare and orphan diseases, has announced the pricing of an underwritten offering of 10,000,000 shares of its common stock at a price of $5.70 per share. After the underwriting discount and estimated offering expenses, Amicus expects to receive net proceeds of approximately $54 million. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock. The offering is expected to close on March 7, 2012, subject to customary closing conditions. Dechert LLP is advising Leerink Swann LLC and Cowen and Company, LLC as underwriters in the offering.
The Dechert team advising Leerink Swann and Cowen and Company includes James Lebovitz and Gregory Schernecke (Corporate and Securities) as well as Thomas Rayski and Rebecca Wais (Intellectual Property).